Bortezomib for Injection 3.5 mg (Bortezomib (Bortezomib Mannitol Boronic Ester) POWDER FOR SOLUTION) 3.5 MG

Bortezomib for Injection 3.5 mg is a powder for solution used in cancer treatment. This medication, manufactured by Teva Canada Limited, is administered intravenously or subcutaneously.

Strength

3.5 MG

Pack Size

I.V.:3.5ML/S.C:1.4ML

Manufacturer / TM Owner

TEVA CANADA LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bortezomib is primarily used in the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasome activity, which can help slow the growth of cancer cells. Patients often wonder, 'What is Bortezomib used for?' It is typically prescribed as part of a combination therapy for these conditions.

Side Effects

Common effects of Bortezomib may include fatigue, nausea, and peripheral neuropathy. Some patients also experience diarrhea or constipation. These effects can vary in severity and may differ from person to person.

Precautions & Warnings

Bortezomib should be handled with care, as it is a potent medication. It is important to follow the healthcare provider's instructions for administration and storage. Patients should be monitored for signs of infection or bleeding, as this medication can affect the immune system.

Avoid Interactions

Bortezomib may interact with other medications, including those that affect the liver or immune system. It is important to inform your healthcare provider about all medications you are taking. Alcohol and certain foods may also interact with Bortezomib, so it is advisable to discuss dietary restrictions with a healthcare professional.

Frequently Asked Questions

Bortezomib is used in the treatment of multiple myeloma and mantle cell lymphoma. It is often part of a combination therapy.

Bortezomib is administered either intravenously or subcutaneously, depending on the healthcare provider's instructions.

Common side effects include fatigue, nausea, peripheral neuropathy, diarrhea, and constipation.

Bortezomib may interact with other medications, so it is important to inform your healthcare provider about all medications you are taking.

Patients should follow their healthcare provider's instructions for administration and storage. Monitoring for signs of infection or bleeding is also important.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.